Website under construction

EBiSC - European Bank for induced pluripotent Stem Cells


The EBiSC consortium announces the official launch of the project. Read more in the press release ...

About the EBiSC project

EBiSC is designed to address the increasing demand by induced Pluripotent Stem Cell (iPSC) researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cost-efficient and customised products.

The EBiSC Consortium including EFPIA partners boasts the leadership, scientific expertise, facilities, networks and experience to achieve these goals and, being representative of all stakeholders from tissue donors to clinical and academic iPSC researchers and industrial users, to respond appropriately to advances in science and society. Led by Pfizer Ltd and managed by Roslin Cells, the Consortium comprises 8 active participant iPSC Centres with clinical and patient networks, a global leader in industrial iPSC supply, international experts in iPSC science, biobanking, bioengineering and regenerative medicine, and scholars in law and ethics. The main facility will be at the Babraham Research Campus (Cambridge, UK) and will undertake cell expansion, QC and characterisation. The European Cell Culture Collection (ECACC) of Public Health England (Department of Health, UK) will coordinate cell line distribution. The Fraunhofer IBMT (Saarbrücken, Germany) will provide comprehensive operational back up. Read more about the EBiSC project ...

To express your initial views about what the EBiSC bank should include, take part in the EBiSC user demand survey. For more information, please contact .

Project Partners

EFPIA companies


Universities, research organisations, public bodies, non-profit groups


Please, contact us at:

The EBiSC project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115582, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.